STOCK TITAN

Point72 reports 6.8% Tenax (TENX) stake via 423,415 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Tenax Therapeutics, Inc. received an amended ownership report showing that Point72 Asset Management, Point72 Capital Advisors and Steven A. Cohen beneficially own 423,415 shares of Tenax common stock, representing 6.8% of the outstanding class as of December 31, 2025.

The shares are held by Point72 Associates, LLC, an investment fund managed by Point72 Asset Management, which has investment and voting power under an investment management agreement. Point72 Capital Advisors is the general partner of Point72 Asset Management, and Mr. Cohen controls both entities.

The reporting persons certify that the Tenax shares were not acquired and are not held to change or influence control of the company, but instead are reported on a passive basis under the beneficial ownership rules.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Point72 Asset Management, L.P.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:02/17/2026
Point72 Capital Advisors, Inc.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:02/17/2026
Steven A. Cohen
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:02/17/2026

FAQ

What ownership stake in TENX does Point72 report in this Schedule 13G/A?

Point72-related entities report beneficial ownership of 423,415 shares of Tenax Therapeutics common stock, representing 6.8% of the outstanding class as of December 31, 2025, according to the amended Schedule 13G filing.

Which entities are reporting beneficial ownership of TENX shares?

The filing lists Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen as reporting persons, with the shares held by Point72 Associates, LLC, an investment fund managed by Point72 Asset Management.

How many TENX shares does each reporting person beneficially own?

Each reporting person—Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen—is shown as beneficially owning 423,415 Tenax shares with shared voting and dispositive power, and no sole voting or sole dispositive power reported.

Are the TENX shares held to influence control of Tenax Therapeutics?

The reporting persons certify the Tenax shares were not acquired and are not held for the purpose of changing or influencing control of Tenax Therapeutics, and are not held in connection with any control-related transaction, other than activities tied to a specific nomination rule.

Who ultimately controls the entities holding TENX shares in this filing?

The filing states that Point72 Capital Advisors is the general partner of Point72 Asset Management and that Steven A. Cohen controls both entities, giving him indirect beneficial ownership over the 423,415 Tenax shares held by Point72 Associates.

As of what date is the TENX ownership information in this filing reported?

The ownership information, including the 423,415 shares and 6.8% beneficial ownership, is reported as of the close of business on December 31, 2025, which is identified as the relevant event date in the Schedule 13G/A.
Tenax Therapeutics Inc

NASDAQ:TENX

TENX Rankings

TENX Latest News

TENX Latest SEC Filings

TENX Stock Data

77.61M
5.79M
Biotechnology
Pharmaceutical Preparations
Link
United States
CHAPEL HILL